414 related articles for article (PubMed ID: 33424856)
1. HCoV- and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients.
Steiner S; Sotzny F; Bauer S; Na IK; Schmueck-Henneresse M; Corman VM; Schwarz T; Drosten C; Wendering DJ; Behrends U; Volk HD; Scheibenbogen C; Hanitsch LG
Front Immunol; 2020; 11():607918. PubMed ID: 33424856
[TBL] [Abstract][Full Text] [Related]
2. Reactive T Cells in Convalescent COVID-19 Patients With Negative SARS-CoV-2 Antibody Serology.
Steiner S; Schwarz T; Corman VM; Sotzny F; Bauer S; Drosten C; Volk HD; Scheibenbogen C; Hanitsch LG
Front Immunol; 2021; 12():687449. PubMed ID: 34322120
[TBL] [Abstract][Full Text] [Related]
3. Human Milk Antibodies Against S1 and S2 Subunits from SARS-CoV-2, HCoV-OC43, and HCoV-229E in Mothers with A Confirmed COVID-19 PCR, Viral SYMPTOMS, and Unexposed Mothers.
Demers-Mathieu V; DaPra C; Mathijssen G; A Sela D; M Jarvinen K; Seppo A; Fels S; Medo E
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572480
[TBL] [Abstract][Full Text] [Related]
4. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray.
Camerini D; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Shandling A; Huynh V; Teng AA; Hermanson G; Pablo JV; Stumpf MM; Lester SN; Harcourt J; Tamin A; Rasheed M; Thornburg NJ; Satheshkumar PS; Liang X; Kennedy RB; Yee A; Townsend M; Campo JJ
Microbiol Spectr; 2021 Oct; 9(2):e0141621. PubMed ID: 34704808
[TBL] [Abstract][Full Text] [Related]
5. Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study.
Guo L; Wang Y; Kang L; Hu Y; Wang L; Zhong J; Chen H; Ren L; Gu X; Wang G; Wang C; Dong X; Wu C; Han L; Wang Y; Fan G; Zou X; Li H; Xu J; Jin Q; Cao B; Wang J
Emerg Microbes Infect; 2021 Dec; 10(1):664-676. PubMed ID: 33734013
[TBL] [Abstract][Full Text] [Related]
6. Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post-COVID-19 Convalescent Samples.
Shrwani K; Sharma R; Krishnan M; Jones T; Mayora-Neto M; Cantoni D; Temperton NJ; Dobson SL; Subramaniam K; McNamara PS; Cunliffe NA; Turtle L; Zhang Q
J Infect Dis; 2021 Oct; 224(8):1305-1315. PubMed ID: 34161567
[TBL] [Abstract][Full Text] [Related]
7. Anti-RBD IgG antibodies from endemic coronaviruses do not protect against the acquisition of SARS-CoV-2 infection among exposed uninfected individuals.
Adami FL; de Castro MV; Almeida BDS; Daher IP; Yamamoto MM; Souza Santos K; Zatz M; Naslavsky MS; Rosa DS; Cunha-Neto E; de Oliveira VL; Kalil J; Boscardin SB
Front Immunol; 2024; 15():1396603. PubMed ID: 38846944
[TBL] [Abstract][Full Text] [Related]
8. CD4
Taborska P; Strizova Z; Stakheev D; Sojka L; Bartunkova J; Smrz D
Front Immunol; 2021; 12():629102. PubMed ID: 34012431
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19.
Braun J; Loyal L; Frentsch M; Wendisch D; Georg P; Kurth F; Hippenstiel S; Dingeldey M; Kruse B; Fauchere F; Baysal E; Mangold M; Henze L; Lauster R; Mall MA; Beyer K; Röhmel J; Voigt S; Schmitz J; Miltenyi S; Demuth I; Müller MA; Hocke A; Witzenrath M; Suttorp N; Kern F; Reimer U; Wenschuh H; Drosten C; Corman VM; Giesecke-Thiel C; Sander LE; Thiel A
Nature; 2020 Nov; 587(7833):270-274. PubMed ID: 32726801
[TBL] [Abstract][Full Text] [Related]
10. Healthy donor T cell responses to common cold coronaviruses and SARS-CoV-2.
Woldemeskel BA; Kwaa AK; Garliss CC; Laeyendecker O; Ray SC; Blankson JN
J Clin Invest; 2020 Dec; 130(12):6631-6638. PubMed ID: 32966269
[TBL] [Abstract][Full Text] [Related]
11. The prospect of universal coronavirus immunity: characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses.
Soni MK; Migliori E; Fu J; Assal A; Chan HT; Pan J; Khatiwada P; Ciubotariu R; May MS; Pereira MR; De Giorgi V; Sykes M; Mapara MY; Muranski PJ
Front Immunol; 2023; 14():1212203. PubMed ID: 37901229
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency.
Arroyo-Sánchez D; Cabrera-Marante O; Laguna-Goya R; Almendro-Vázquez P; Carretero O; Gil-Etayo FJ; Suàrez-Fernández P; Pérez-Romero P; Rodríguez de Frías E; Serrano A; Allende LM; Pleguezuelo D; Paz-Artal E
J Clin Immunol; 2022 Feb; 42(2):240-252. PubMed ID: 34787773
[TBL] [Abstract][Full Text] [Related]
13. Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers.
Jackson-Thompson BM; Goguet E; Laing ED; Olsen CH; Pollett S; Hollis-Perry KM; Maiolatesi SE; Illinik L; Ramsey KF; Reyes AE; Alcorta Y; Wong MA; Davies J; Ortega O; Parmelee E; Lindrose AR; Moser M; Graydon E; Letizia AG; Duplessis CA; Ganesan A; Pratt KP; Malloy AM; Scott DW; Anderson SK; Snow AL; Dalgard CL; Powers JH; Tribble D; Burgess TH; Broder CC; Mitre E
BMC Infect Dis; 2021 Jun; 21(1):544. PubMed ID: 34107889
[TBL] [Abstract][Full Text] [Related]
14. Functional SARS-CoV-2 cross-reactive CD4
Humbert M; Olofsson A; Wullimann D; Niessl J; Hodcroft EB; Cai C; Gao Y; Sohlberg E; Dyrdak R; Mikaeloff F; Neogi U; Albert J; Malmberg KJ; Lund-Johansen F; Aleman S; Björkhem-Bergman L; Jenmalm MC; Ljunggren HG; Buggert M; Karlsson AC
Proc Natl Acad Sci U S A; 2023 Mar; 120(12):e2220320120. PubMed ID: 36917669
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa.
Tso FY; Lidenge SJ; Peña PB; Clegg AA; Ngowi JR; Mwaiselage J; Ngalamika O; Julius P; West JT; Wood C
Int J Infect Dis; 2021 Jan; 102():577-583. PubMed ID: 33176202
[TBL] [Abstract][Full Text] [Related]
16. Impact of Previous Common Human Coronavirus Exposure on SARS-CoV-2-Specific T-Cell and Memory B-Cell Response after mRNA-Based Vaccination.
Casado JL; Vizcarra P; Martín-Hondarza A; Blasco M; Grandal-Platero M; Haemmerle J; Fernández-Escribano M; Vallejo A
Viruses; 2023 Feb; 15(3):. PubMed ID: 36992336
[TBL] [Abstract][Full Text] [Related]
17. Previous viral symptoms and individual mothers influenced the leveled duration of human milk antibodies cross-reactive to S1 and S2 subunits from SARS-CoV-2, HCoV-229E, and HCoV-OC43.
Demers-Mathieu V; DaPra C; Mathijssen GB; Medo E
J Perinatol; 2021 May; 41(5):952-960. PubMed ID: 33649442
[TBL] [Abstract][Full Text] [Related]
18. Seroprevalence and SARS-CoV-2 cross-reactivity of endemic coronavirus OC43 and 229E antibodies in Finnish children and adults.
Tamminen K; Salminen M; Blazevic V
Clin Immunol; 2021 Aug; 229():108782. PubMed ID: 34118402
[TBL] [Abstract][Full Text] [Related]
19. Specific Antibody and the T-Cell Response Elicited by BNT162b2 Boosting After Two ChAdOx1 nCoV-19 in Common Variable Immunodeficiency.
Goda V; Kriván G; Kulcsár A; Gönczi M; Tasnády S; Matula Z; Nagy G; Bekő G; Horváth M; Uher F; Szekanecz Z; Vályi-Nagy I
Front Immunol; 2022; 13():907125. PubMed ID: 35784359
[TBL] [Abstract][Full Text] [Related]
20. Age-Associated Seroprevalence of Coronavirus Antibodies: Population-Based Serosurveys in 2013 and 2020, British Columbia, Canada.
Tanunliong G; Liu AC; Kaweski S; Irvine M; Reyes RC; Purych D; Krajden M; Morshed M; Sekirov I; Gantt S; Skowronski DM; Jassem AN
Front Immunol; 2022; 13():836449. PubMed ID: 35401521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
